Amlodipine/bisoprolol

Drug Profile

Amlodipine/bisoprolol

Alternative Names: Bisoprolol/amlodipine; Concor-AM

Latest Information Update: 08 Jul 2015

Price : $50

At a glance

  • Originator Merck KGaA
  • Class Antihypertensives; Dihydropyridines; Heart failure therapies; Ischaemic heart disorder therapies; Propanolamines; Small molecules
  • Mechanism of Action Beta 1 adrenergic receptor antagonists; Calcium channel antagonists; Cytochrome P 450 enzyme system inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Essential hypertension

Most Recent Events

  • 01 Mar 2015 Merck completes a phase III trial for Essential hypertension in Germany (NCT01977794)
  • 01 Mar 2014 Phase-III clinical trials in Essential hypertension in Germany (PO) (NCT01977794)
  • 31 Oct 2013 Merck plans a phase III trial for Essential hypertension in Germany (NCT01977794)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top